Abiopharma

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of: (1) Midkine antibodies with significant in vivo efficacy and toxicology studies; (2) Midkine RNA therapeutics with novel anti-cancer gene editing action; (3) Midkine mRNA therapeutics with novel anti-cancer approach; (4) STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and (5) MK cell therapy with direct and natural killer cell-mediated anti-cancer action.

Additional info from OTC:
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of: (1) Midkine antibodies with significant in vivo efficacy and toxicology studies; (2) Midkine RNA therapeutics with novel anti-cancer gene editing action; (3) Midkine mRNA therapeutics with novel anti-cancer approach; (4) STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and (5) MK cell therapy with direct and natural killer cell-mediated anti-cancer action.